Peptide vaccines against cancer are described herein. In particular isolated epitope peptides or immunogenic fragments derived from SEQ ID NO: 32 that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) are provided. The amino acid sequence of the peptide of interest may be optionally modified with the substitution deletion insertion or addition of one two or several amino acids sequences. Pharmaceutical compositions and methods of treating cancer that include such peptides are also provided.
